About Ankylosing Spondylitis
Symptom Management
Living with AS
Cimzia (Certolizumab Pegol)
Cosentyx (Secukinumab)
Cyltezo (Adalimumab-adbm) for Ankylosing Spondylitis
Ixifi (Infliximab-qbtx)
Remicade (Infliximab)
Remsima (Infliximab)
Simponi (Golimumab)
Taltz (ixekizumab)
Arcoxia (Etoricoxib)
Bimekizumab (CDP-4940; UCB-4940)
Filgotinib
Namilumab for Ankylosing Spondylitis
Netakimab (BCD-085)
Upadacitinib (ABT-494)
Xeljanz (Tofacitinib Citrate)
Kicking AS
A Wellness Journey
Persevering with AS
Hypertension, Depression More Common in Patients Than Others of Same Age and Sex, Study Reports
by Patricia Inacio, PhD
In Just Published, News.
Click here to subscribe to the Ankylosing Spondylitis News Newsletter!
Ankylosing spondylitis patients carry a significantly higher burden for several comorbidities — other diseases — than are found in people without this inflammatory disorder of the same age and sex, a study drawing on real-world medical data reports.
Comorbidities seen to have the highest incidence rates among ankylosing spondylitis patients included hypertension, dyslipidemia (abnormal amount of fat), and depression.
The study,"Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set," was published in the Clinical Rheumatology.
Medical records from two large U.S. administrative claims databases — MarketScan Commercial Claims and Encounters (Commercial) and Medicare Supplemental (Medicare) databases — were analyzed to compare the prevalence and incidence of comorbidities between ankylosing spondylitis patients and matched controls (people without the disease) from the general population.
Controls matched patients' age, geographic region, index calendar year, and sex.
The records included inpatient services, outpatient services, long-term care, and prescription drug claims. The analysis included records on 6,679 people with ankylosing spondylitis, matched with records from 19,951 controls. All were followed for a median of two years.
Average age was 50.8 for ankylosing spondylitis patients and 51.7 for the others. Around 60 percent of both patients and controls were males – 60.8% and 60.5%, respectively.
Ankylosing spondylitis patients had a higher rate of comorbidities, as shown by higher scores in the Deyo-Charlson Comorbidity Index — a method of categorizing comorbidities according to the International Classification of Diseases (ICD) diagnosis codes.
Among the comorbidities, or other diseases, observed were asthma, cardiovascular diseases, depression, dyslipidemia, gastrointestinal ulcers, malignancies, multiple sclerosis, osteoporosis, sleep apnea, spinal fracture, inflammatory bowel disease (IBD), psoriasis, and uveitis (inflammation of the middle layer of the eye, called the uvea).
Peripheral vascular disease, diabetes, and Parkinson disease affected both ankylosing spondylitis and controls to a similar degree.
But IBD and uveitis were eight and 26 times higher, respectively, in patients with ankylosing spondylitis than in matched controls.
Multiple sclerosis, osteoporosis, and spinal fracture were three- to four-times more likely to affect ankylosing spondylitis patients, which also showed two-times higher incidence rates of asthma, depression, gastrointestinal ulcers, sleep apnea, and venous thromboembolism (a condition where a blood clot forms in a vein).
Among ankylosing spondylitis patients, men and women showed differences in comorbidities: women had an increased risk of developing asthma, depression and osteoporosis, while cardiovascular disease, dyslipidemia, hypertension, malignancies, sleep apnea, and spinal fracture were more common in men.
"On this real-world, US claims-based study, patients with ankylosing spondylitis were shown to have significantly more comorbidities than matched controls," the researchers wrote.
"This study did not examine the causality of the association between AS and comorbidities. A potential explanation is that patients have shared genetic or environmental risk factors that predispose them to both AS and to the comorbidities," they noted.
"Other possibilities are that AS may increase the risk of the evaluated comorbidities or that AS may be a marker for or consequence of unidentified risk factors that contribute to the risk of both AS and the comorbidities," the authors concluded.
Patricia Inacio, PhD
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Tagged comorbidities, depression, Deyo-Charlson Comorbidity Index, hypertension.
Previous: Lupin Seeks EU Marketing Approval for YLB113, Etanercept Biosimilar, for Ankylosing Spondylitis
Next:Social Media Allows Glimpse into AS Patients' Thoughts on Biologics
Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients
Sex Differences Found in nr-axSpA Disease Severity, Treatment Response
Rinvoq Recommended for EU Approval to Treat Active AS
CHMP Favors At-home Injection Form of Remsima for Europe
Cosentyx Approved in US to Treat Active nr-axSpA
FDA Approves Taltz for Non-radiographic Axial Spondyloarthritis
Ankylosing Spondylitis News
Ankylosing Spondylitis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.